-+ 0.00%
-+ 0.00%
-+ 0.00%

Eli Lilly plans to submit a bioproduct license application for retaglutide to the US Food and Drug Administration in the first quarter of 2027. According to Lilly, retaglutide achieved significant weight loss effects, and retaglutide reached the main end in the phase III trial.

Zhitongcaijing·07/23/2026 10:49:06
Listen to the news
Eli Lilly plans to submit a bioproduct license application for retaglutide to the US Food and Drug Administration in the first quarter of 2027. According to Lilly, retaglutide achieved significant weight loss effects, and retaglutide reached the main end in the phase III trial.